Sugi Predict

Sugi Predict / Compounds / SCHEMBL170812

SCHEMBL170812

SCHEMBL170812

C[C@]1(O)[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1O

nearest known ligand 0.38

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 5/20 0.38
▸ ADORA3 P0DMS8 7/20 0.37
▸ ADORA1 P30542 5/20 0.37
▸ ADORA2B P29275 4/20 0.37
▸ ALOX15 P16050 1/20 0.33
▸ ADA P00813 1/20 0.30
▸ CDA P32320 5/20 0.30
▸ ALDH1A1 P00352 2/20 0.30
▸ TSHR P16473 2/20 0.30
▸ LMNA P02545 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3995295 1.00 ADORA2A (0.38) ADORA2AADORA3ADORA1ADORA2BALOX15
SCHEMBL19404182 1.00 ADORA2A (0.38) ADORA2AADORA3ADORA1ADORA2BALOX15
SCHEMBL6040254 1.00 ADORA2A (0.38) ADORA2AADORA3ADORA1ADORA2BALOX15
SCHEMBL18241620 1.00 ADORA2A (0.38) ADORA2AADORA3ADORA1ADORA2BALOX15
SCHEMBL7640916 1.00 ADORA2A (0.38) ADORA2AADORA3ADORA1ADORA2BALOX15
SCHEMBL338344 0.80 ADORA2A (0.38) ADORA2AADORA3ADORA1ADORA2BALOX15
SCHEMBL1826901 0.80 ADORA2A (0.38) ADORA2AADORA3ADORA1ADORA2BALOX15
SCHEMBL338345 0.80 ADORA2A (0.38) ADORA2AADORA3ADORA1ADORA2BALOX15
SCHEMBL14293911 0.80 ADORA2A (0.38) ADORA2AADORA3ADORA1ADORA2BALOX15
SCHEMBL8722910 0.79 ADORA2A (0.36) ADORA2AADORA3ADORA1ADORA2BALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024060271-A1 CHARACTERISTIC IMPURITY IN EMPAGLIFLOZIN BULK DRUG OR PREPARATION AND USE THEREOF 浙江宏元药业股份有限公司 2024-03-28 — — WO disclosed
EP-2968258-B1 DUAL SGLT1/SGLT2 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-02-12 — — EP disclosed
EP-2968258-A1 DUAL SGLT1/SGLT2 INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2016-01-20 — — EP disclosed
US-9012412-B2 Dual SGLT1/SGLT2 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-04-21 — — US disclosed
CN-104284894-A Novel pyrazole compounds LILLY CO ELI 2015-01-14 — — CN disclosed
WO-2014164286-A1 DUAL SGLT1/SGLT2 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-09 — — WO disclosed
US-20140256657-A1 DUAL SGLT1/SGLT2 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-11 — — US disclosed
CN-101501053-B 1- (-D-glucopyranosyl) -3- (4-cyclopropylphenylmethyl) -4-haloindole derivatives and their use as SGLT inhibitors MITSUBISHI TANABE PHARMA CORP 2012-10-03 — — CN disclosed
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-08 — — US disclosed
CN-102234260-A C-aryl glucoside derivatives containing difluoromethylene group SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD 2011-11-09 — — CN disclosed
US-7910619-B2 e.g. 2,3,4,6-tetra-O-benzyl-5-thio-D-glucono-1,5-lactone3,4-Dihydro-2H-pyran; inhibit the activity of sodium-dependent glucose cotransporter 2 (SGLT2) concerned with glucose reabsorption in the kidney; antidiabetic agent; diabetes-related disease, or diabetic complication TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-03-22 — — US disclosed
EP-2049557-B1 1- (-D-GLYCOPYRANOSYL) - 3 - (4-CYCLOPROPYLPHENYLMETHYL) - 4 - HALOGENO INDOLE DERIVATIVES AND USE THEREOF AS SGLT INHIBITORS. MITSUBISHI TANABE PHARMA CORP (JP) 2011-03-09 — — EP disclosed
CN-101111492-B Indole derivatives TANABE SEIYAKU CO 2010-09-22 — — CN disclosed
CN-101501053-A 1- (-D-glucopyranosyl) -3- (4-cyclopropylphenylmethyl) -4-haloindole derivatives and their use as SGLT inhibitors MITSUBISHI TANABE PHARMA CORP (JP) 2009-08-05 — — CN disclosed
US-7465713-B2 Glucopyranosyloxypyrazole derivatives and use thereof in medicines KISSEI PHARMACEUTICAL CO., LTD. (JP) 2008-12-16 — — US disclosed
CN-101111492-A Indole derivatives TANABE SEIYAKU CO (JP) 2008-01-23 — — CN disclosed
EP-1695088-A1 METHOD FOR ANALYSING METABOLITES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2006-08-30 — — EP disclosed
WO-2005059556-A1 METHOD FOR ANALYSING METABOLITES MAX PLANCK GESELLLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) 2005-06-30 — — WO disclosed
EP-1405859-A1 NITROGENOUS HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE THEREFOR Kissei Pharmaceutical Co., Ltd. (JP) 2004-04-07 — — EP disclosed
US-6037333-A INHIBITING AN INFECTION BY A MICROORGANISM BY ADMINISTERING PHARMACEUTICALLY EFFECTIVE AMOUNT OF N-ACETYLGLUCOSAMINE TRUSTEES OF TUFTS COLLEGE (US) 2000-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 ADORA2A 1452/4885ADORA3 1587/4885ADORA1 1209/4885
US-20140256657-A1 DUAL SGLT1/SGLT2 INHIBITORS SLC5A1, SLC5A2, GLP1R ADORA2A 1935/4885ADORA3 907/4885ADORA1 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.